Global Drug Repositioning Market Overview And Scope:
Global Drug Repositioning Market Size was estimated at USD 27547.31 million in 2022 and is projected to reach USD 36385.53 million by 2028, exhibiting a CAGR of 4.75% during the forecast period.
The Global Drug Repositioning Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Drug Repositioning utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Teva, Novartis, Mylan, Johnson and Johnson, Pfizer, Bausch Health, GSK, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma
Global Drug Repositioning Market Segmentation
By Type, Drug Repositioning market has been segmented into:Generic Drugs
Clinical Trial Failed Drugs
By Application, Drug Repositioning market has been segmented into:
Cardiovascular Diseases
Mental Illness
Cancer
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Drug Repositioning market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Drug Repositioning market.
Top Key Players Covered in Drug Repositioning market are:
Teva
Novartis
Mylan
Johnson and Johnson
Pfizer
Bausch Health
GSK
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Objective to buy this Report:
1. Drug Repositioning analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Drug Repositioning market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Drug Repositioning Market by Type
5.1 Drug Repositioning Market Overview Snapshot and Growth Engine
5.2 Drug Repositioning Market Overview
5.3 Generic Drugs
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Generic Drugs: Geographic Segmentation
5.4 Clinical Trial Failed Drugs
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Clinical Trial Failed Drugs: Geographic Segmentation
Chapter 6: Drug Repositioning Market by Application
6.1 Drug Repositioning Market Overview Snapshot and Growth Engine
6.2 Drug Repositioning Market Overview
6.3 Cardiovascular Diseases
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Cardiovascular Diseases: Geographic Segmentation
6.4 Mental Illness
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Mental Illness: Geographic Segmentation
6.5 Cancer
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Cancer: Geographic Segmentation
6.6 Others
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Drug Repositioning Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Drug Repositioning Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Drug Repositioning Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 TEVA
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 NOVARTIS
7.4 MYLAN
7.5 JOHNSON AND JOHNSON
7.6 PFIZER
7.7 BAUSCH HEALTH
7.8 GSK
7.9 CHEMRAR GROUP
7.10 GLENMARK
7.11 FUJIFILM
7.12 DR. REDDY
7.13 R-PHARMA
Chapter 8: Global Drug Repositioning Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Generic Drugs
8.2.2 Clinical Trial Failed Drugs
8.3 Historic and Forecasted Market Size By Application
8.3.1 Cardiovascular Diseases
8.3.2 Mental Illness
8.3.3 Cancer
8.3.4 Others
Chapter 9: North America Drug Repositioning Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Generic Drugs
9.4.2 Clinical Trial Failed Drugs
9.5 Historic and Forecasted Market Size By Application
9.5.1 Cardiovascular Diseases
9.5.2 Mental Illness
9.5.3 Cancer
9.5.4 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Drug Repositioning Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Generic Drugs
10.4.2 Clinical Trial Failed Drugs
10.5 Historic and Forecasted Market Size By Application
10.5.1 Cardiovascular Diseases
10.5.2 Mental Illness
10.5.3 Cancer
10.5.4 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Drug Repositioning Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Generic Drugs
11.4.2 Clinical Trial Failed Drugs
11.5 Historic and Forecasted Market Size By Application
11.5.1 Cardiovascular Diseases
11.5.2 Mental Illness
11.5.3 Cancer
11.5.4 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Drug Repositioning Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Generic Drugs
12.4.2 Clinical Trial Failed Drugs
12.5 Historic and Forecasted Market Size By Application
12.5.1 Cardiovascular Diseases
12.5.2 Mental Illness
12.5.3 Cancer
12.5.4 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Drug Repositioning Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Generic Drugs
13.4.2 Clinical Trial Failed Drugs
13.5 Historic and Forecasted Market Size By Application
13.5.1 Cardiovascular Diseases
13.5.2 Mental Illness
13.5.3 Cancer
13.5.4 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Drug Repositioning Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Generic Drugs
14.4.2 Clinical Trial Failed Drugs
14.5 Historic and Forecasted Market Size By Application
14.5.1 Cardiovascular Diseases
14.5.2 Mental Illness
14.5.3 Cancer
14.5.4 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Drug Repositioning Scope:
|
Report Data
|
Drug Repositioning Market
|
|
Drug Repositioning Market Size in 2025
|
USD XX million
|
|
Drug Repositioning CAGR 2025 - 2032
|
XX%
|
|
Drug Repositioning Base Year
|
2024
|
|
Drug Repositioning Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Teva, Novartis, Mylan, Johnson and Johnson, Pfizer, Bausch Health, GSK, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma.
|
|
Key Segments
|
By Type
Generic Drugs
Clinical Trial Failed Drugs
By Applications
Cardiovascular Diseases
Mental Illness
Cancer
Others
|
